Olema Pharmaceuticals (Olema Pharmaceuticals) Short-Term Debt & Capital Lease Obligation : $0.99 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Olema Pharmaceuticals Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Olema Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.99 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Olema Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.43 Mil.

Olema Pharmaceuticals Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Olema Pharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olema Pharmaceuticals Short-Term Debt & Capital Lease Obligation Chart

Olema Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.93

1.02

0.99

Olema Pharmaceuticals Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial														1.02	0.91	0.80	0.92	0.99

Olema Pharmaceuticals Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Olema Pharmaceuticals Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Olema Pharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Olema Pharmaceuticals (Olema Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olema Pharmaceuticals inc (NAS:OLMA) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

512, 2nd Street, 4th Floor, San Francisco, CA, USA, 94107

Website

https://www.olema.com

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.

Executives

Cyrus Harmon	director, officer: Chief Technology Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Paradigm Biocapital Advisors Lp	10 percent owner	767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017
G. Walmsley Graham	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kovacs Shane William Charles	officer: Ch. Operating & Financial Off.	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Naseem Zojwalla	officer: Chief Medical Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Sean Bohen	director, officer: President and CEO	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
David C. Myles	officer: Chief Development Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Senai Asefaw	10 percent owner	767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Paradigm Biocapital International Fund Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Biotechnology Value Fund L P	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Paradigm Biocapital Advisors Gp Llc	10 percent owner	767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Kinney Horn	officer: Chief Business Officer	C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Yi Larson	director	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116